$50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to biopharmaceutical research, development, and manufacturing for infectious disease products."
You can find more data on corporate lobbying on Quiver Quantitative.
VIR Insider Trading Activity
VIR insiders have traded $VIR stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $VIR stock by insiders over the last 6 months:
- ENDURANCE (CAYMAN) LTD SVF has made 0 purchases and 8 sales selling 1,343,547 shares for an estimated $7,869,826.
- VICKI L SATO has made 0 purchases and 4 sales selling 88,000 shares for an estimated $460,112.
- MARK EISNER (EVP and Chief Medical Officer) has made 0 purchases and 2 sales selling 10,382 shares for an estimated $56,790.
- JANET NAPOLITANO sold 3,200 shares for an estimated $16,148
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
VIR Hedge Fund Activity
We have seen 100 institutional investors add shares of VIR stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARCH VENTURE MANAGEMENT, LLC added 12,916,663 shares (+inf%) to their portfolio in Q2 2025, for an estimated $65,099,981
- CITADEL ADVISORS LLC added 1,847,689 shares (+114.3%) to their portfolio in Q2 2025, for an estimated $9,312,352
- FMR LLC added 1,342,221 shares (+60.6%) to their portfolio in Q2 2025, for an estimated $6,764,793
- ROYAL BANK OF CANADA added 683,864 shares (+2927.2%) to their portfolio in Q2 2025, for an estimated $3,446,674
- NORDEA INVESTMENT MANAGEMENT AB added 564,537 shares (+403.7%) to their portfolio in Q2 2025, for an estimated $2,845,266
- GOLDMAN SACHS GROUP INC added 547,464 shares (+73.7%) to their portfolio in Q2 2025, for an estimated $2,759,218
- ENSIGN PEAK ADVISORS, INC added 519,107 shares (+812.7%) to their portfolio in Q2 2025, for an estimated $2,616,299
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
VIR Analyst Ratings
Wall Street analysts have issued reports on $VIR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/15/2025
- Raymond James issued a "Outperform" rating on 07/11/2025
- Needham issued a "Buy" rating on 05/22/2025
To track analyst ratings and price targets for VIR, check out Quiver Quantitative's $VIR forecast page.
VIR Price Targets
Multiple analysts have issued price targets for $VIR recently. We have seen 5 analysts offer price targets for $VIR in the last 6 months, with a median target of $14.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $15.0 on 09/15/2025
- Cory Kasimov from Evercore ISI Group set a target price of $12.0 on 09/03/2025
- Geoff Meacham from B of A Securities set a target price of $14.0 on 08/27/2025
- Sean McCutcheon from Raymond James set a target price of $12.0 on 07/11/2025
- Joseph Stringer from Needham set a target price of $14.0 on 05/22/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
